Treatment of symptoms in multiple sclerosis

REFERENCES

• Crayton H, Heyman RA, Rossman HS. A mult imodal approach to managing the symptoms of multiple sclerosis. Neurology2004; 63 (11 Suppl. 5): S12—S18
   Google Scholar
• Tullman M. Symptomatic therapy in multiple sclerosis. Continuum 2004; 10: 142–172
   Google Scholar
• Krupp LB. Fatigue in multiple sclerosis: Definition, pathophysiol-ogy and treatment. CNS Drugs 2003; 17: 225–234
   PubMed Web of Science ®Google Scholar
• Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol 2003; 13: 265–270
   Google Scholar
• Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432–441
   PubMed Web of Science ®Google Scholar
• Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62: 2058–2064
   PubMed Web of Science ®Google Scholar
• Beenakker E, Oparina T, Hartgring A, et al. Cooling garment treatment in MS: Clinical improvement and decrease in leukocyte no production. Neurology 2001; 57: 892–894
   PubMed Web of Science ®Google Scholar
• Schwid SR, Petrie MD, Murray R, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for multiple sclerosis. Neurology 2003; 60: 1955–1960
   PubMed Web of Science ®Google Scholar
• A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. Can] Neurol Sci 1987; 14: 273–278
   PubMed Web of Science ®Google Scholar
• Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676–680
   PubMed Web of Science ®Google Scholar
• Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: Results of a double-blind, randomized, parallel trial of amantadine, pemoline and placebo. Neurology 1995; 45: 1956–1961
   PubMed Web of Science ®Google Scholar
• Taus C, Giuliani G, Pucci E, et al. Amantadine in multiple sclerosis. Cochrane Database Syst Rev 2003; (2): CD002818
   Google Scholar
• Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72: 179–183
   PubMed Web of Science ®Google Scholar
• Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002; 249: 983–987
   PubMed Web of Science ®Google Scholar
• Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakeful-ness. J Neurosci 2000; 20: 8620–8628
   PubMed Web of Science ®Google Scholar
• Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study. Neurology 2005; 64:1139–1143
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468–1471
   PubMed Web of Science ®Google Scholar
• Berkovitch M, Pope E, Phillips J, et al. Pemoline-associated fulminant liver failure: Testing the evidence for causation. Clin Pharmacol Ther 1995; 57: 696–698
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertelsmann FW, van Loenen AC, et al. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994; 51: 292–296
   PubMed Web of Science ®Google Scholar
• Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: Results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scier 2001; 7: 354–358
   PubMed Web of Science ®Google Scholar
• Bever CT, Jr, Anderson PA, Leslie J, et al. Treatment with 3,4 diaminopyridine in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996; 47: 1457–1462
   PubMed Web of Science ®Google Scholar
• Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomized, double-blind, crossover trial. J Neurol Sci 2004; 218: 103–108
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005; 64: 1267–1269
   PubMed Web of Science ®Google Scholar
• Paisley S, Beard S, Hunn A, et al. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: A systematic review. Mult Scler 2002; 8: 319–329
   PubMed Web of Science ®Google Scholar
• Bramanti P, Sessa E, Rifici C, et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 1998; 51: 1720–1723
   PubMed Web of Science ®Google Scholar
• Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehab 2000; 81: 164–169
   PubMed Web of Science ®Google Scholar
• Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomized, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707–712
   PubMed Web of Science ®Google Scholar
• Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75: 951–957
   PubMed Web of Science ®Google Scholar
• Coffey RJ, Cahil D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J Neurosurg 1993; 78: 226–232
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomized placebo-controlled trial. Lancet 2003; 362: 1517–1526
   PubMed Web of Science ®Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Syst Rev 2001; (4): CD001332
   Google Scholar
• DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: Management strategies. Drugs 2003; 63: 153–166
   PubMed Web of Science ®Google Scholar
• Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53: 1270–1275
   PubMed Web of Science ®Google Scholar
• Fowler CJ. Intravesical treatment of the overactive bladder. Urology 2000; 55: 60–64
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Beck RO, Gerrard S, et al. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57: 169–173
   PubMed Web of Science ®Google Scholar
• Dykstra DD, Pryor J, Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: A case report. Arch Phys Med Rehabil 2003; 84: 1399–1400
   PubMed Web of Science ®Google Scholar
• Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692–697
   PubMed Web of Science ®Google Scholar
• Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scier 2004; 10: 425–433
   PubMed Web of Science ®Google Scholar
• Finger WW, Lund M, Slagle MA. Medications that may contribute to sexual disorders. A Guide to assessment and treatment in family practice. J Fam Pract 1997; 44: 33–43
   PubMed Web of Science ®Google Scholar
• Fowler C, Miller J, Sharief M. Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis. Ann Neurol 1999; 46: 497
   Web of Science ®Google Scholar
• Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998; 159: 122–124
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, Hellstron WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl] Med 1997; 336: 1–7
   PubMed Web of Science ®Google Scholar
• Ganem JP, Lucey DT, Janosko EO, et al. Unusual complications of the vacuum erection device. Urology 1998; 51: 627–631
   PubMed Web of Science ®Google Scholar
• Lillius H, Valtonen C, Wilkstrom J. Sexual problems in patients suffering from multiple sclerosis. J Chron Dis 1976; 19: 643–647
   Google Scholar
• Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modifi-cation of psychosexual dysfunction. J Sex Marital Ther 1987; 13: 239–252
   PubMed Web of Science ®Google Scholar
• Caruso S, Intelisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: A double-blind, cross-over, placebo-controlled study. BJOG 2001; 108: 623–628
   PubMed Web of Science ®Google Scholar
• Krupp LB, Rizvi SA. Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology 2002; 58 (8 Suppl. 4): S32—S39
   Google Scholar
• Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996; 46: 628–632
   PubMed Web of Science ®Google Scholar
• Amato MP, Zipoli V. Clinical management of cognitive impair-ment in multiple sclerosis: A review of current evidence. Int MS J 2003; 10: 72–83
   PubMedGoogle Scholar
• Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579–1585
   PubMed Web of Science ®Google Scholar
• Alusi Sh, Worthington J, Glickman S, et al. A study of tremor in multiple sclerosis. Brain 2001; 124: 720–730
   PubMed Web of Science ®Google Scholar
• Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62: 1105–1109
   PubMed Web of Science ®Google Scholar
• Wishart HA, Roberts DW, Roth RM, et al. Chronic deep brain stimulation for the treatment of tremor in multiple sclerosis: A review and case reports. J Neurol Neurosurg Psychiatry 2003; 74: 1392–1397
   PubMed Web of Science ®Google Scholar
• Hooper J, Whittle IR. Costs of thalamic deep brain stimulation for movement disorders in patients with multiple sclerosis. Br J Neurosurg 2003; 17: 40–45
   PubMed Web of Science ®Google Scholar
• Rice GP, Lesaux J, Vandervoort P, et al. Ondansetron, a 5-HT3 antagonist improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997; 62: 282–284
   PubMed Web of Science ®Google Scholar
• Jain S, Proudlock F, Constantinescu CS, et al. Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. Am Ophthal 2002; 134: 780–782
   PubMed Web of Science ®Google Scholar
• Straube A. Pharmacology of vertigo/nystagmus/oscillopsia. Curr Opin Neurol 2005; 18: 11–14
   PubMed Web of Science ®Google Scholar
• Starck M, Albrecht H, Pollmann W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 1996; 244: 9–16
   Web of Science ®Google Scholar
• Svendsen KB, Jansen TS, Overvad K, et al. Pain in patients with multiple sclerosis: A population based study. Arch Neurol 2003; 60: 1089–1094
   PubMedGoogle Scholar
• Berk C, Constantoyann is C, Honey CR. The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy. Can] Neurol Sci 2003; 30: 220–223
   PubMed Web of Science ®Google Scholar
• Broggi G, Ferroli P, Franzini A, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery 2004; 55: 830-83862 Rogers CL, Shetter AG, Ponce FA, et al. Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis. J Neurosurg 2002; 97: 529–532
   Google Scholar
• Thompson AL Neurorehabilitation in multiple sclerosis: Foundations, facts and fiction. Curr Opin Neurol 2005; 18: 267–271
   PubMed Web of Science ®Google Scholar
• Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005; 4: 643–652
   PubMed Web of Science ®Google Scholar
• Thompson AL Symptomatic management and rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71 (Suppl. 2): ii22—ii27
   Google Scholar